Secretory leukocyte peptidase inhibitor as a dynamic radiotherapy response biomarker in esophageal squamous cell carcinoma
MedScience · 2026-04 · 20 (2) · 311-328
DOI: 10.1007/s11684-026-1211-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedScience, online erschienen am 20.04.2026. Verfasst von Hongming Deng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cell and Molecular Biology & State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for C…. Hauptthemen laut MEDLINE: Secretory Leukocyte Peptidase Inhibitor, Biomarkers, Tumor, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma. Die Arbeit nennt 90 Literaturangaben.
Abstract (Originalsprache)
Esophageal cancer is the seventh leading cause of cancer-related deaths, with most cases diagnosed at locally advanced stages. Chemoradiotherapy is one of the most effective treatments for these patients. However, high rates of recurrence persist, highlighting the need for more reliable prognostic biomarkers. In this study, we identified immune-related prognostic genes through bulk (n = 119) and single-cell (n = 60) transcriptomic analyses. We then used Western blotting, enzyme-linked immunosorbent assay (ELISA), and immunofluorescence to preliminarily investigate the potential biological functions of the candidate biomarker. The clinical prognostic utility of the candidate biomarker was validated in an independent cohort (n = 91) via ELISA of serum samples collected before and during chemoradiotherapy. The results showed that low expression of the secretory leukocyte peptidase inhibitor (SLPI) significantly correlated with tumor progression and poor prognosis. In epithelial cells, reduced SLPI expression was associated with decreased activation of differentiation-related pathways. Furthermore, SLPI expression levels were found to influence fibroblast phenotypes, with exogenous SLPI inhibiting the NF-κB pathway and restoring fibroblast quiescence. The results of ELISA showed that dynamic changes in serum SLPI levels during chemoradiotherapy serve as an independent prognostic factor. In conclusion, serum SLPI levels represent an easy-to-detect biomarker for dynamically monitoring the efficacy of chemoradiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Cell and Molecular Biology & State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking…
- State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking…
- Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin, 300060, China.
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer /Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
- Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Zitieren
APA
Deng, H., Li, J., Gao, L. R., Huang, N., Wang, C., Xiao, Z., Wang, X., Wang, L., Xiao, T., & Liu, M. (2026). Secretory leukocyte peptidase inhibitor as a dynamic radiotherapy response biomarker in esophageal squamous cell carcinoma. MedScience, 20(2), 311-328. https://doi.org/10.1007/s11684-026-1211-5
Vancouver
Deng H, Li J, Gao LR, Huang N, Wang C, Xiao Z, et al. Secretory leukocyte peptidase inhibitor as a dynamic radiotherapy response biomarker in esophageal squamous cell carcinoma. MedScience. 2026;20(2):311-328. doi:10.1007/s11684-026-1211-5
BibTeX
@article{Deng2026,
author = {Deng, Hongming and Li, Junyi and Gao, Lin-Rui and Huang, Ning and Wang, Chenxi and Xiao, Zefen and Wang, Xiaobing and Wang, Liming and Xiao, Ting and Liu, Mei},
title = {Secretory leukocyte peptidase inhibitor as a dynamic radiotherapy response biomarker in esophageal squamous cell carcinoma},
journal = {MedScience},
year = {2026},
volume = {20},
number = {2},
pages = {311--328},
doi = {10.1007/s11684-026-1211-5}
}
EUVIMED